Insmed sees brensocatib NDA for bronchiectasis in Q4
2024-07-03
magicmine Insmed (NASDAQ:INSM) said it plans to submit a New Drug Application to the U.S. FDA for brensocatib as a treatment for the chronic lung condition bronchiectasis in Q4. The decision follows additional positive results from the phase 3 ASPEN study. In late May, the company announced the candidate metContinue Reading